Bibliographic Details
| Title: |
Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study |
| Authors: |
Rungroj Krittayaphong, Arjbordin Winijkul, Komsing Methavigul, Wattana Wongtheptien, Chaiyasith Wongvipaporn, Treechada Wisaratapong, Rapeephon Kunjara-Na-Ayudhya, Smonporn Boonyaratvej, Chulalak Komoltri, Pontawee Kaewcomdee, Ahthit Yindeengam, Piyamitr Sritara, for the COOL-AF Investigators |
| Source: |
BMC Cardiovascular Disorders, Vol 18, Iss 1, Pp 1-6 (2018) |
| Publisher Information: |
BMC, 2018. |
| Publication Year: |
2018 |
| Collection: |
LCC:Diseases of the circulatory (Cardiovascular) system |
| Subject Terms: |
Risk profiles, Antithrombotics, Non-valvular atrial fibrillation, Thailand, Diseases of the circulatory (Cardiovascular) system, RC666-701 |
| More Details: |
Abstract Background Anticoagulation therapy is a standard treatment for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) that have risk factors for stroke. However, anticoagulant increases the risk of bleeding, especially in Asians. We aimed to investigate the risk profiles and pattern of antithrombotic use in patients with NVAF in Thailand, and to study the reasons for not using warfarin in this patient population. Methods A nationwide multicenter registry of patients with NVAF was created that included data from 24 hospitals located across Thailand. Demographic data, atrial fibrillation-related data, comorbid conditions, use of antithrombotic drugs, and reasons for not using warfarin were collected. Data were recorded in a case record form and then transferred into a web-based system. Results A total of 3218 patients were included. Average age was 67.3 ± 11.3 years, and 58.2% were male. Average CHADS2, CHA2DS2-VASc, and HAS-BLED score was 1.8 ± 1.3, 3.0 ± 1.7, and 1.5 ± 1.0, respectively. Antiplatelet was used in 26.5% of patients, whereas anticoagulant was used in 75.3%. The main reasons for not using warfarin in those with CHA2DS2-VASc ≥2 included already taking antiplatelet (26.6%), patient preference (23.1%), and using non-vitamin K antagonist oral anticoagulants (NOACs) (22.7%). Anticoagulant was used in 32.3% of CHA2DS2-VASc 0, 56.8% of CHA2DS2-VASc 1, and 81.6% of CHA2DS2-VASc ≥2. The use of NOACs increased from 1.9% in 2014 to 25.6% in 2017. Conclusions Anticoagulation therapy was prescribed in 75.3% of patients with NVAF. Among those receiving anticoagulant, 90.9% used warfarin and 9.1% used NOACs. The use of NOACs increased over time. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1471-2261 |
| Relation: |
http://link.springer.com/article/10.1186/s12872-018-0911-4; https://doaj.org/toc/1471-2261 |
| DOI: |
10.1186/s12872-018-0911-4 |
| Access URL: |
https://doaj.org/article/f6a1417b635f40bcbfca444fde789aae |
| Accession Number: |
edsdoj.f6a1417b635f40bcbfca444fde789aae |
| Database: |
Directory of Open Access Journals |
